KROS logo

Keros Therapeutics (KROS)

Profile

Full Name

Keros Therapeutics, Inc.

Ticker Symbol

KROS

Exchange

NASDAQ

Country

United States

IPO

April 8, 2020

Indexes

Not included

Employees

169

Key Details

Price

$12.18(-0.49%)

Market cap

$494.05M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$3.55M(+2250.99% YoY)

Annual EPS

-$5.00(+3.85% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Apr 9, 25 Truist Securities
Buy
Apr 1, 25 Wedbush
Neutral
Apr 1, 25 HC Wainwright & Co.
Buy
Feb 27, 25 Wells Fargo
Overweight
Feb 27, 25 HC Wainwright & Co.
Buy
Jan 21, 25 Cantor Fitzgerald
Neutral
Jan 17, 25 Wedbush
Neutral
Jan 17, 25 Piper Sandler
Overweight
Jan 17, 25 Guggenheim
Neutral
Jan 16, 25 Scotiabank
Sector Outperform

Institutional Ownership

  • What is the ticker symbol for Keros Therapeutics?
  • Does Keros Therapeutics pay dividends?
  • What sector is Keros Therapeutics in?
  • What industry is Keros Therapeutics in?
  • What country is Keros Therapeutics based in?
  • When did Keros Therapeutics go public?
  • Is Keros Therapeutics in the S&P 500?
  • Is Keros Therapeutics in the NASDAQ 100?
  • Is Keros Therapeutics in the Dow Jones?
  • When was Keros Therapeutics's last earnings report?
  • When does Keros Therapeutics report earnings?
  • Should I buy Keros Therapeutics stock now?

What is the ticker symbol for Keros Therapeutics?

The ticker symbol for Keros Therapeutics is NASDAQ:KROS

Does Keros Therapeutics pay dividends?

No, Keros Therapeutics does not pay dividends

What sector is Keros Therapeutics in?

Keros Therapeutics is in the Healthcare sector

What industry is Keros Therapeutics in?

Keros Therapeutics is in the Biotechnology industry

What country is Keros Therapeutics based in?

Keros Therapeutics is headquartered in United States

When did Keros Therapeutics go public?

Keros Therapeutics's initial public offering (IPO) was on April 8, 2020

Is Keros Therapeutics in the S&P 500?

No, Keros Therapeutics is not included in the S&P 500 index

Is Keros Therapeutics in the NASDAQ 100?

No, Keros Therapeutics is not included in the NASDAQ 100 index

Is Keros Therapeutics in the Dow Jones?

No, Keros Therapeutics is not included in the Dow Jones index

When was Keros Therapeutics's last earnings report?

Keros Therapeutics's most recent earnings report was on Feb 26, 2025

When does Keros Therapeutics report earnings?

The next expected earnings date for Keros Therapeutics is May 8, 2025

Should I buy Keros Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page